Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of ad...

Full description

Bibliographic Details
Main Authors:	Yvonne Peijun Zhou, Nathalie Grace Sy Chua, Maciej Piotr Chlebicki, Winnie Hui Ling Lee, Andrea Lay Hoon Kwa
Format:	Article
Language:	English
Published:	Hindawi Limited 2014-01-01
Series:	Case Reports in Infectious Diseases
Online Access:	http://dx.doi.org/10.1155/2014/573279

id	doaj-bea4efea37044977b2865604d3948b55
record_format	Article
spelling	doaj-bea4efea37044977b2865604d3948b552020-11-24T22:46:09ZengHindawi LimitedCase Reports in Infectious Diseases2090-66252090-66332014-01-01201410.1155/2014/573279573279Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal FailureYvonne Peijun Zhou0Nathalie Grace Sy Chua1Maciej Piotr Chlebicki2Winnie Hui Ling Lee3Andrea Lay Hoon Kwa4Department of Pharmacy, Singapore General Hospital, Outram Road, 169608, SingaporeDepartment of Pharmacy, Singapore General Hospital, Outram Road, 169608, SingaporeDepartment of Infectious Diseases, Singapore General Hospital, Outram Road, 169608, SingaporeDepartment of Pharmacy, Singapore General Hospital, Outram Road, 169608, SingaporeDepartment of Pharmacy, Singapore General Hospital, Outram Road, 169608, SingaporeRecent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented.http://dx.doi.org/10.1155/2014/573279
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Yvonne Peijun Zhou Nathalie Grace Sy Chua Maciej Piotr Chlebicki Winnie Hui Ling Lee Andrea Lay Hoon Kwa
spellingShingle	Yvonne Peijun Zhou Nathalie Grace Sy Chua Maciej Piotr Chlebicki Winnie Hui Ling Lee Andrea Lay Hoon Kwa Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure Case Reports in Infectious Diseases
author_facet	Yvonne Peijun Zhou Nathalie Grace Sy Chua Maciej Piotr Chlebicki Winnie Hui Ling Lee Andrea Lay Hoon Kwa
author_sort	Yvonne Peijun Zhou
title	Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_short	Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_full	Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_fullStr	Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_full_unstemmed	Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure
title_sort	nonattenuated polymyxin b used for the treatment of extreme-drug resistant acinetobacter baumannii-related infections in patients with preexisting end stage renal failure
publisher	Hindawi Limited
series	Case Reports in Infectious Diseases
issn	2090-6625 2090-6633
publishDate	2014-01-01
description	Recent pharmacokinetic studies have suggested that nonrenal clearance predominates the elimination of polymyxin B. We present 2 patients with preexisting end stage renal failure, who were given nonattenuated doses of polymyxin B for the treatment of extreme-drug resistant organism. No evidence of adverse events occurred and microbiological clearance was documented.
url	http://dx.doi.org/10.1155/2014/573279
work_keys_str_mv	AT yvonnepeijunzhou nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure AT nathaliegracesychua nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure AT maciejpiotrchlebicki nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure AT winniehuilinglee nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure AT andrealayhoonkwa nonattenuatedpolymyxinbusedforthetreatmentofextremedrugresistantacinetobacterbaumanniirelatedinfectionsinpatientswithpreexistingendstagerenalfailure
_version_	1725686046914510848

Nonattenuated Polymyxin B Used for the Treatment of Extreme-Drug Resistant Acinetobacter baumannii-Related Infections in Patients with Preexisting End Stage Renal Failure

Similar Items